11 patents
Utility
Oligosaccharide Formulations of Kappa Opioid Receptor Agonists
30 Nov 23
The invention provides formulations for oral delivery of a therapeutic wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer.
Bryan R. WILSON, Stephen J. O'CONNOR
Filed: 30 May 23
Utility
Oral Formulations of Kappa Opioid Receptor Agonists
26 Oct 23
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride.
Bryan R. WILSON, Stephen J. O’CONNOR
Filed: 20 Jun 23
Utility
Kappa Opioid Receptor Agonist-therapeutic Antigen Binding Protein Conjugate (Ktac) Compounds
12 Oct 23
Conjugate (KTAC) compounds that include a peptidic kappa opioid receptor agonist linked through a protease-sensitive linker and/or acid-sensitive linker to an antibody molecule are provided.
Derek T CHALMERS, Michael E. LEWIS
Filed: 1 Jun 21
Utility
Atopic Dermatitis Therapy with Kappa Opioid Receptor Agonist As Adjunct to Topical Corticosteroid
14 Sep 23
The invention relates to a method of treatment of atopic dermatitis in a patient, the method includes providing a course of treatment comprising orally administering an effective amount of a kappa opioid receptor agonist (KORA) to the patient and applying an effective amount of a topical corticosteroid (TCS) to an area of the patient affected by the atopic dermatitis.
Joana Goncalves, Kristine E. Nograles, Derek T. Chalmers
Filed: 28 Apr 22
Utility
Oral formulations of kappa opioid receptor agonists
27 Jun 23
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride.
Bryan R. Wilson, Stephen J. O'Connor
Filed: 28 Apr 21
Utility
Oral Formulations of Kappa Opioid Receptor Agonists
11 Nov 21
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride.
Bryan R. WILSON, Stephen J. O'CONNOR
Filed: 28 Apr 21
Utility
Oligosaccharide Formulations of Kappa Opioid Receptor Agonists
23 Sep 21
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer.
Bryan R. WILSON, Stephen J. O'CONNOR
Filed: 18 Mar 21
Utility
Oral formulations of kappa opioid receptor agonists
15 Jun 21
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride.
Bryan R. Wilson, Stephen J. O'Connor
Filed: 13 Sep 19
Utility
Synthetic peptide amides and dimers thereof
9 Feb 21
Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
Filed: 9 Jul 18
Utility
Synthetic peptide amides
5 Oct 20
Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
Filed: 25 Nov 18
Utility
Oral Formulations of Kappa Opioid Receptor Agonists
18 Mar 20
The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride.
Bryan R. WILSON, Stephen J. O'CONNOR
Filed: 12 Sep 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first